Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amicus Therapeutics raises $55mm with Series C round

Executive Summary

Amicus Therapeutics (develops small-molecule drugs for genetic disorders) raised $55mm through a Series C financing round led by Quaker BioVentures. Also participating in the round were other new backers Palo Alto Investors and the Garden State Life Sciences Venture Fund (managed by the New Jersey Economic Development Authority), and existing shareholders Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, New Enterprise Associates, Prospect Venture Partners, and Radius Ventures.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies